A Study of Pembrolizumab + sEphB4 in Metastatic Urothelial Carcinoma
Phase 2
38
about 5.4 years
18+
1 site in CA
What this study is about
This trial is testing a treatment with Pembrolizumab and sEphB4-HSA for people with advanced urothelial carcinoma who cannot have chemotherapy or do not want to. The goal is to see if this combination can help slow the growth of cancer cells.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Pembrolizumab + sEphB4-HSA
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer)
infusion
Primary: Estimate of the overall response rate (ORR) of the combination of Pembrolizumab + sEphB4-HSA in the patients with previously untreated advanced (metastatic or recurrent) urothelial carcinoma who are chemotherapy ineligible or who refuse chemotherapy
Secondary: To estimate the overall survival (OS) in these patients, To estimate the progression free survival (PFS) in these patients